GSK - Pharma Boss Aims For 14% Returns On Late Stage Pipeline

LONDON, February 4 - GlaxoSmithKline today said it had posted a strong performance in a
challenging year with a return to sales growth for the first time since 2007.

In an interview on www.cantos.com CEO Andrew Witty also announced
a reduction in the investment into treatments for pain and depression and a
restructuring of R&D.

He said:

"Now obviously I don't like to see anybody leave the organisation or
there to be any job losses. But the reality is that we do, from time to time,
need to look at ways in which we can improve our probability of success."

The interview and transcript are available now on www.cantos.com.

Cantos.com, the online financial broadcaster, features in-depth
interviews, documentaries and webcasts with senior company executives. If you
would like to contact us, please email amanda.alexander@cantos.com or phone
+44-207-936-1352.

If you would like to contact us, please email amanda.alexander at cantos.com or phone
+44-207-936-1352.